ArticleCancer discovery2019
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 1 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
202 citing papers in PubMed, 1 synthesis or guideline pooled it, 297 citations in OpenAlex.
- Pooled it
- Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer.Frontiers in immunology · 2025Trial
- PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.Journal for immunotherapy of cancer · 2023Trial
- Trial
- A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer.Cancer research and treatment · 2022Trial
- Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.Frontiers in immunology · 2022Trial
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.The Lancet. Oncology · 2020Trial
- Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.Pharmaceutical science advances · 2026Review
- Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.Immunology · 2026Review
- Review
- Umbilical cord blood-derived natural killer cells:Annals of medicine and surgery (2012) · 2026Article
- Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.Cancer medicine · 2026Article
- Mannose-binding lectin 2 secreted by hepatocellular carcinoma cells recruits and activates natural killer cells to reshape an immune-activated microenvironment.PLoS biology · 2026Article
- Emerging Immunotherapy and Antibody-Derived Therapeutics for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review.Cancers · 2026Review
- Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.Cancer cell international · 2026Article
- Natural Killer Cell Dysregulation During ALS Disease Progression: A Gene Expression Analysis.Neurology open access · 2026Article
- PD-L1 is an intrinsic switch for natural killer cell-mediated, TRAIL-dependent antiviral function.Cell reports · 2026Article
- BACH2 alleviates immune checkpoint inhibitors-induced cardiac pyroptosis via transcriptionally promoting GRSF1.Clinical and translational medicine · 2026Article
- Ultrasensitive biosensor based on AgNPs-functionalized perylene derivative nanosheets with enhanced electrochemiluminescence at narrow potential sweep range.Mikrochimica acta · 2026Article
- PD‑L1 deficient exosomes derived from lung cancer cell line enhances NK cell‑mediated anti‑tumor immunity against lung cancer.Cell communication and signaling : CCS · 2026Article
142 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Wenjuan Dong *Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Xiaojin Wu *The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Shoubao Ma *Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Yufeng Wang *The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ansel P NalinMedical Scientist Training Program, The Ohio State University, Columbus, Ohio.ORCID 0000-0001-5673-0203
Zheng ZhuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Jianying ZhangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California.
Don M BensonThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Kai HeThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Michael A CaligiuriDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California. mcaligiuri@coh.org jiayu@coh.org.
Jianhua YuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California. mcaligiuri@coh.org jiayu@coh.org.
City Of Hope National Medical Center · USThe Ohio State University · USSoochow University · CN
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MThe Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI KEITH LLOYD LIGON · 2013 to 2026
$26.0MHuman natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3MIL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5MCharacterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK CellsR01CA247550 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2020 to 2024
$2.2MElucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1MOvercoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9MEnhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer PreventionR01CA185301 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 2015 to 2019
$1.8MIL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4MscFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid LeukemiaR21CA223400 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2019 to 2020
$414kNCI NIH HHS P01 CA163205NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA068458NCI NIH HHS R01 CA185301NCI NIH HHS R01 CA247550NCI NIH HHS R21 CA223400NCI NIH HHS R35 CA210087NCI NIH HHS R37 CA068458NIAID NIH HHS R01 AI129582NINDS NIH HHS R01 NS106170
Abstract
Blockade of PD-L1 expression on tumor cells via anti-PD-L1 monoclonal antibody (mAb) has shown great promise for successful cancer treatment by overcoming T-cell exhaustion; however, the function of PD-L1 on natural killer (NK) cells and the effects of anti-PD-L1 mAb on PD-L1
Indexed as
AnimalsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCell Line, TumorCytokinesCytotoxicity, ImmunologicGene ExpressionHumansImmunophenotypingKiller Cells, NaturalLymphocyte ActivationNeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalatezolizumabB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCytokinesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.